OAM
ZVRA icon

Oxford Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Oxford Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,219
Closed -$63K – 2034
2018
Q4 		$63K Buy
+2,219
New +$89.8K ﹤0.01% 1688

Other funds holding ZVRA

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Oxford Asset Management's ZVRA Position: Q1 2019 in Review

Oxford Asset Management sold out of Zevra Therapeutics (ZVRA) in Q1 2019, closing a stake of 2,219 shares — an estimated $63K sold.

Oxford Asset Management first reported a position in ZVRA in Q4 2018 and held it in 1 quarter. The position peaked at $63K in Q4 2018. 38 funds tracked by Wall St. Rank hold ZVRA as of Q1 2019.

  • Oxford Asset Management reported no remaining Zevra Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Oxford Asset Management sold 2,219 Zevra Therapeutics shares in Q1 2019, an estimated $63K.
  • Oxford Asset Management first reported a position in Zevra Therapeutics in Q4 2018 and held it in 1 quarter.
  • Oxford Asset Management's Zevra Therapeutics position peaked at $63K in Q4 2018.
  • 38 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.